Royalty Pharma plcRPRX

Key ratios

Operating cash flow growth

23.7%TTM

2025 -10.1%2024 -7.3%2023 39.4%

EPS growth

-20.0%TTM

2025 -6.8%2024 -24.5%2023 2490.7%

FCF / Sales

117.4%TTM

2025 104.7%2024 122.3%2023 126.9%

Net margin

32.0%TTM

2025 32.4%2024 38.0%2023 48.2%

ROA

5.1%TTM

2025 5.2%2024 4.7%2023 5.6%

ROE

14.0%TTM

2025 13.2%2024 13.0%2023 17.3%

Revenue growth

10.0%TTM

2025 5.1%2024 -3.9%2023 5.2%

Track RPRX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer